We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$39.3B
1-Year Est. Return
27.96%
This Fund
S&P 500
This Quarter
Est. Return
+13.03%
1 Year Est. Return
+27.96%
3 Year Est. Return
+58.37%
5 Year Est. Return
+80.22%
10 Year Est. Return
+439.89%
AUM
$39.3B
AUM Growth
+$3.7B
(+10%)
Cap. Flow
+$2.27B
Cap. Flow
% of AUM
5.78%
Top 10 Holdings %
Top 10 Hldgs %
11.24%
Holding
2,749
New
386
Increased
1,048
Reduced
996
Closed
125
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$393M |
| 2 |
AngloGold Ashanti
AU
|
+$356M |
| 3 |
General Dynamics
GD
|
+$348M |
| 4 |
NVIDIA
NVDA
|
+$202M |
| 5 |
Kroger
KR
|
+$198M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$441M |
| 2 |
CVS Health
CVS
|
+$424M |
| 3 |
United Parcel Service
UPS
|
+$359M |
| 4 |
Devon Energy
DVN
|
+$243M |
| 5 |
Target
TGT
|
+$194M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.71% |
| 2 | Miscellaneous | 16.91% |
| 3 | Healthcare | 12.7% |
| 4 | Consumer Discretionary | 10.42% |
| 5 | Communication Services | 7.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Recursion Pharmaceuticals
RXRX
$1.95B
| $38K | ﹤0.01% |
+10,248
| New | +$34.1K |
|
|
NVMI
1277
Nova
NVMI
$11.8B
| $37K | ﹤0.01% |
68
+32
| +89% | +$16.4K |
|
1278
Arcus Biosciences
RCUS
$3.78B
| $37K | ﹤0.01% |
+1,198
| New | +$29.6K |
|
1279
Sarepta Therapeutics
SRPT
$2.38B
| $37K | ﹤0.01% |
+2,065
| New | +$39.1K |
|
1280
Syndax Pharmaceuticals
SNDX
$1.84B
| $36K | ﹤0.01% |
+1,633
| New | +$34K |
|
1281
Arcutis Biotherapeutics
ARQT
$3B
| $35K | ﹤0.01% |
+1,349
| New | +$31.4K |
|
1282
Celldex Therapeutics
CLDX
$3.12B
| $35K | ﹤0.01% |
+938
| New | +$30.3K |
|
1283
Global E Online
GLBE
$6.44B
| $35K | ﹤0.01% |
1,007
+131
| +15% | +$4.14K |
|
1284
Mineralys Therapeutics
MLYS
$2.49B
| $35K | ﹤0.01% |
+1,306
| New | +$35.8K |
|
1285
Agios Pharmaceuticals
AGIO
$1.98B
| $34K | ﹤0.01% |
+928
| New | +$28.2K |
|
1286
ACM Research
ACMR
$5.18B
| $33K | ﹤0.01% |
+262
| New | +$18.5K |
|
1287
monday.com
MNDY
$3.85B
| $33K | ﹤0.01% |
451
+11
| +3% | +$806 |
|
1288
NMI Holdings
NMIH
$3.37B
| $33K | ﹤0.01% |
808
-198
| -20% | -$7.57K |
|
1289
Novavax
NVAX
$1.69B
| $33K | ﹤0.01% |
+3,486
| New | +$31.2K |
|
1290
Viridian Therapeutics
VRDN
$2.6B
| $33K | ﹤0.01% |
+1,816
| New | +$29.3K |
|
1291
Disc Medicine
IRON
$3.04B
| $32K | ﹤0.01% |
+444
| New | +$30.5K |
|
|
UCTT
1292
Ultra Clean Holdings
UCTT
$3.28B
| $31K | ﹤0.01% |
+214
| New | +$18.8K |
|
1293
Immunome
IMNM
$3.04B
| $29K | ﹤0.01% |
+1,389
| New | +$29.7K |
|
|
PVLA
1294
Palvella Therapeutics
PVLA
$2.27B
| $29K | ﹤0.01% |
+190
| New | +$23.1K |
|
1295
Absci
ABSI
$1.51B
| $28K | ﹤0.01% |
+2,401
| New | +$13.5K |
|
1296
Iovance Biotherapeutics
IOVA
$3.98B
| $28K | ﹤0.01% |
+6,729
| New | +$25.6K |
|
1297
Nurix Therapeutics
NRIX
$2.71B
| $28K | ﹤0.01% |
+1,142
| New | +$19.5K |
|
|
CNR
1298
Core Natural Resources Inc
CNR
$4.94B
| $28K | ﹤0.01% |
344
+41
| +14% | +$3.63K |
|
1299
Kodiak Sciences
KOD
$2.22B
| $27K | ﹤0.01% |
+694
| New | +$27K |
|
1300
Biohaven
BHVN
$2.37B
| $26K | ﹤0.01% |
+1,760
| New | +$18.9K |
|
Similar funds
PPF
CS
Pacer Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Pacer Advisors held 2,749 positions worth $39.3B, up 10% from $35.6B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Pacer Advisors deployed $2.27B of net new capital in Q2 2026, opening 386 new positions and adding to 1,048 existing holdings. Its largest new stake was AngloGold Ashanti: 3,744,168 shares worth $303M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was ConocoPhillips, an estimated $441M trimmed.
- Pacer Advisors's largest Q2 2026 buy was AngloGold Ashanti: 3,744,168 shares worth $303M.
- Pacer Advisors added most to Lowe's Companies in Q2 2026, an estimated $393M increase.
- Pacer Advisors's biggest Q2 2026 reduction was ConocoPhillips, cutting an estimated $441M.
- Pacer Advisors fully exited Coterra Energy in Q2 2026, selling an estimated $118M.
- Pacer Advisors's ten largest holdings make up 11% of its $39.3B portfolio in Q2 2026.
- Pacer Advisors opened 386 new positions and closed 125 in Q2 2026.
- Pacer Advisors's portfolio value rose 10% quarter-over-quarter to $39.3B.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.